Latest filing published 25 Apr 2012 for Sarepta Therapeutics, Inc..
Insider track record
No signal scores available.
Closed purchases
Based on 2 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- +654.6%Entry US$3.24 · Close at T+365 US$24.45
- -33.3%Entry US$9.72 · Close at T+365 US$6.48
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Nishan Garabedian Christopher: trading record in brief
Nishan Garabedian Christopher is a declared insider of Sarepta Therapeutics, Inc., with filings sourced from SEC (Form 4). In total, 4 filings cover trades dated from 6 April 2011 to 27 February 2015.
No open-market sale appears; the market trades are 3 purchases worth €278k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Other entries cover 1 share grant. Since January 2015: 1 purchase and no sales on the market.
A typical purchase (the median) is worth €134k.
On 3 March 2015 came the latest disclosure, an open-market purchase for €8,439 in Sarepta Therapeutics, Inc. Filings reach the SEC (Form 4) feed a median of 1 day after the trade. Section 16 rules allow two business days to file each Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Nishan Garabedian Christopher
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 81,666 shares0Common StockSEC:0000873303-12-000005:0
- 300,000 shares@ US$0.5788Common StockSEC:0000873303-11-000049:0Canonical exit: 14 Mar 2012 (T+90)
- 130,000 shares@ US$1.50Common StockSEC:0000873303-11-000012:0Canonical exit: 5 Jul 2011 (T+90)
3 of 3 declarations
